Moleculin Announces Reverse Stock Split

Authorized common shares will remain at 500 million after the reverse split.

Rhea-AI Summary

Moleculin Biotech (MBRX) announced a 1-for-20 reverse stock split taking effect on October 20, 2026, at 12:01 a.m. Eastern Time.

Split-adjusted trading will begin that day on The Nasdaq Capital Market. Outstanding common shares will fall from approximately 20.9 million to approximately 1.05 million. The company filed the certificate amendment in Delaware to effect the split.

News Explained

A reverse split consolidates shares and proportionally raises the per-share price; the split itself does not change company value.

The amendment is filed and the 1-for-20 split is scheduled for October 20, 2026; authorized common shares remain at 500 million while outstanding shares are consolidated. Holders otherwise entitled to fractional shares will receive cash instead of fractional shares.

Argus 15 min delay 7 alerts

-14.91% vs previous close $0.31 last price 5.0x rel. volume Open Argus

Details

Market move: MBRX -14.91% vs previous close. 1-for-20 reverse stock split

$0.30 – $0.38 Day Range

$6.42M Market Cap

On Oct 16, the day this news came out, the latest delayed price for MBRX is 14.91% below the previous close. Our momentum scanner has recorded 7 alerts for this stock so far that day. The latest delayed price is $0.31. Relative volume is exceptionally heavy at 5.0x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Reverse split ratio: 1-for-20 Effective date: October 20, 2026 Outstanding shares: Approximately 20.9 million to approximately 1.05 million shares +1 more

Reverse split ratio

1-for-20

Common stock

Effective date

October 20, 2026

Reverse split takes effect at 12:01 am Eastern Time

Outstanding shares

Approximately 20.9 million to approximately 1.05 million shares

Before and after the reverse split

Authorized shares

500 million shares

Remains unchanged after the reverse split

Previous Stock split Reports

1 past event · Latest: Nov 26

Same Type 1 event

1. Nov 26

   Reverse stock split

   24h Move

   -22.0%

   Prior 1-for-25 reverse split used the same consolidation and cash-in-lieu structure

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cusip number, par value

2 terms

cusip number technical

"under the existing ticker symbol “MBRX” but with a new CUSIP number 60855D 507"

A CUSIP number is a nine-character code that uniquely identifies a specific U.S. or Canadian stock, bond, or other security, similar to a barcode or a social-security number for a financial instrument. It matters to investors because it removes confusion between similar securities, ensures trades and settlements are applied to the correct issue, and helps locate official documents and transaction records quickly.

par value financial

"with no change to the nominal par value per share of $0.001"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on October 20, 2026, and the Company’s common stock will open for trading on The Nasdaq Capital Market on October 20, 2026 on a post-split basis, under the existing ticker symbol “MBRX” but with a new CUSIP number 60855D 507.

As a result of the reverse stock split, every 20 shares of the Company’s common stock issued and outstanding prior to the opening of trading on October 20, 2026 will be consolidated into one issued and outstanding share, with no change in the nominal par value per share of $0.001. No fractional shares will be issued if, as a result of the reverse stock split, a stockholder would become entitled to a fractional share because the number of shares of common stock they hold before the reverse stock split is not evenly divisible by the split ratio. Instead, the stockholder will be entitled to receive a cash payment in lieu of a fractional share.

As a result of the reverse stock split, the number of shares of common stock outstanding will be reduced from approximately 20.9 million shares to approximately 1.05 million shares, and the number of authorized shares of common stock will remain at 500 million shares.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), has shown to be an efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company is conducting the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine (also referred to as “Ara-C”), together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway toward a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing and completion of the reverse split, and the Company’s anticipated need for significant additional financing. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Moleculin's reverse stock split take effect, and what is the ratio?

Moleculin's 1-for-20 reverse stock split takes effect at 12:01 a.m. Eastern Time on October 20, 2026. Every 20 outstanding common shares will become one share, with split-adjusted trading beginning that day on The Nasdaq Capital Market.

How will Moleculin handle fractional shares in the reverse stock split?

Stockholders entitled to a fractional share will receive cash instead. No fractional shares will be issued when a holder's pre-split share count is not evenly divisible by the split ratio.